THE VISION To restore energy, build strength, and renew the spirit through faith-driven, personalized hydration, fitness, nutrition, and regenerative care
Abbreviations ACPs: Anticancer peptides PDCs: Peptidedrug conjugates HNP-1: Human neutrophil peptide LfcinB: Lactoferrin GHRH: Growth hormone-releasing hormone STAT3: Signal transducer and activator of transcription 3 GSH: Glutathione ADCs: Antibodydrug conjugates mAb: Monoclonal antibody USFDA: US Food and Drug Administration BBB: Bloodbrain barrier SORT1: Sortilin 1 DTX: Docetaxel NSCLC: Non-small cell lung cancer HDM-2: Human double minute 2 Apaf-1: Apoptotic protease-activating factor-1 ROS: Reactive oxygen species TP53: Tumor protein 53 AIF: Apoptosis-inducing factor EndoG: Endonuclease G PLP2: Proteolipid protein 2 DAMPs: Damage-associated molecular patterns HMGB1: High-mobility group protein B1 VEGF: Vascular endothelial growth factor PDGF: Platelet-derived growth factor FGF: Fibroblast growth factor CK2: Casein kinase 2 MMP: Matrix metalloproteinase VEGF-A: Vascular endothelial growth factor ALA-A2: Alpha-lactalbumin-A2 IC50: Half maximal inhibitory concentration DCs: Dendritic cells Treg: Regulatory T cell IFN-: Interferon-gamma HLA: Human leukocyte antigen IL-2: Interleukin-2 PEG: Polyethylene glycol MOMP: Mitochondrial outer membrane permeabilization Cyt c: Cytochrome c AIF: Apoptotic-inducing factor mPTP: Mitochondrial permeability transition pore IMM: Inner mitochondria membrane VDAC: Voltage-dependent anion channels MTD: Mitochondrial-targeting domain UCPVax: Universal cancer peptide-based vaccine RhoC: Ras homolog gene family member C SSRT2: Somatostatin receptor-2 References Abdelmageed MI, Abdelmoneim AH, Mustafa MI, Elfadol NM, Murshed NS, Shantier SW, Makhawi AM (2020) Design of a multiepitope-based peptide vaccine against the E protein of human COVID-19: an immunoinformatics approach
The Phase 2 trial showed 22.8% average body weight reduction at 48 weeks in the 8mg group
However, to facilitate coordination of Medicare and Medicaid services, the Medicare Improvements for Patients and Providers Act (MIPPA) of 2008--as amended by the Patient Protection and Affordable Care Act--required all DSNPs to have contracts with the states in which they operate (CMS, 2016b)
